The Scientist - Home

Sidebar:NCI Divisional Structure Amid a swirl of controversy over leadership, budget priorities, and stifling bureaucracy, the new organizational structure of the National Cancer Institute (NCI) went into effect October 1. The reorganization was prompted by internal, agency, and congressional studies. Under the restructuring, many programs, laboratories, and branches fall under new or redesigned divisions, with an eye toward streamlining the agency, revamping its intramural program, and openin

Peace Prizes Author: Karen Young Kreeger Sidebar: 1995 Scientific Laureates Last month's announcements of the 1995 Nobel Prize recipients in the sciences were greeted with hearty approval by scientists from various sectors of the research community. Many of these investigators felt a sense of validation for their fields in the selection committees' choices. In physiology or medicine, the burgeoning discipline of developmental biology was recognized, and the subdiscipline of atmospheric chemi

When Michael Smith took a share of the Nobel Prize in physiology or medicine in 1993 for his work in reprogramming genes, 1989 Nobelist J. Michael Bishop, University Professor in the department of microbiology and immunology at the University of California, San Francisco, offered some friendly advice: Learn to say "no." JUST SAY NO: 1993 laureate Michael Smith was advised to turn down invitations. Previous Nobel laureates warn that the attention and instant celebrity in the first year-even up

Sidebar: Major Pharmaceutical Companies Are Diving Into the Gene Therapy Pool As gene therapy enters its sixth year of high-visibility research, major drug companies are buying in, helping lay the technology's foundation and launching clinical trials. More than 100 gene therapy trials-most privately funded-are under way. And while the field's ultimate success is still quite uncertain, one thing is clear: There is a lot of science to be done and research opportunities to be pursued. ACADEMIA, I

therapy pool Here are a few of the recent deals: The Giant The Gene Therapy Co. The Deal Biogen Inc. Genovo Inc. Seed money: $38 million, 5 years Bristol-Myers Somatix Therapy Corp. Initial $10 million Squibb Co. stock purchase Ciba-Geigy Chiron Corp. 49.9% stake for Ltd. $2.1 billion Glaxo Sequana Therapeutics Undisclosed Wellcome Inc. Megabios Corp. milestone Spectra Biomedical Inc. payments Merck & Co. Vical Inc. $10.4 million Inc. invested to date Rh’ne-Poulenc 14 gene therapy firms

Vitality, Resilience Author: Catherine Didion EDITOR'S NOTE: In September Didion, executive director of the Association for Women in Science (AWIS), was among an AWIS delegation attending the United Nations Fourth World Conference on Women in Beijing, China, and the Non Governmental Organization Forum held in the small town of Huairou, an hour from Beijing. Noting that the torrential rain in Huairou -- the effects of which were exacerbated by the uncomfortable conference facilities -- and pa

In Science Author: Robert Finn Sidebar: PROPORTION OF FULL PROFESSORS AMONG FORMER POSTDOCTORAL FELLOWS IN ACADEMIC SCIENCE A recently released study from Harvard University examining the careers of scientists who showed high promise as postdocs has found persistent gender differences in career outcomes. The study, called Project Access, reveals clear evidence of a glass ceiling for women in certain fields, notes differences in publication patterns, and elucidates the way that family-related

Another Lasker Legacy Dedicated The Next Best Thing to Being There Turbine With A Twist Big Barbie and No-Neck Ken French Foundation Funding Renaissance Scientist NIGMS Web Site MacHome Page Brookhaven As Curator A GOOD NAME: The new biotech building honors biomedical activist Mary Lasker The late Mary Lasker, renowned for her devotion to the cause of advancing biomedical research, was honored with the dedication of a science-park building in her memory on November 2. New York City's first

Laboratories and Branches Director, Richard Klausner Deputy Director, Alan Rabson Legislative Liaison, Dorothy Tisevich Associate Director for Strategic Planning, Edward Sondik Office of Extramural Management Associate Director, Philip D. Amoruso Office of Intramural Management Associate Director, MaryAnn Guerra Office of Cancer Communications Associate Director, J. Paul Van Nevel International Cancer Information Center Associate Director, Susan Hubbard Office of International Affairs Associat

F. Sherwood Rowland - Chemistry Mario J. Molina - Chemistry Christiane Nüsslein-Volhard - Physiology or Medicine Frederick Reines - Physics Joseph Rotblat - Peace Paul Crutzen - Chemistry Martin L. Perl - Physics Eric F. Wieschaus - Physiology or Medicine

FELLOWS IN ACADEMIC SCIENCE MEN WOMEN Biology PSME* Social Biology PSME* Social Sciences Sciences Ph.D. Pre-1978: 0.57 0.70 0.83 0.43 0.37 0.50 N**=56 N=105 N=24 N=23 N=19 N=14 Ph.D. 1978 and After: 0.03 0.10 0.33 0.04 0.00 0.00 N=32 N=89 N=9 N=28 N=16 N=8 *Physical sciences, mathematics, and engineering ** Number of respondents (The Scientist, Vol:9, #22, pg.9 , November 13, 1995) (Copyright © The Scientist, Inc.)

Strategies Author: Karen Young Kreeger SIDEBAR: Significant Recent Biotech Product Approvals Amid a year of continuing hostile capital markets and product failures, biotech executives are retrenching, planning, and implementing scaled-down business plans they hope will sustain their industry into the next century. Their primary strategy to endure is to adopt tactics that are less reliant on public financing and the drug-approval process, according to the 10th annual Ernst and Young report on